Annovis Bio Inc. ANVS Archives

MondayFeb 03, 2025 8:55 am

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $21 Million Public Offering

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing treatments for neurodegenerative diseases, has priced an underwritten public offering of 5.25 million shares of common stock and warrants at a combined price of $4 per share. The warrants, exercisable at $5 per share for five years, are expected to generate gross proceeds of $21 million before deducting expenses. ThinkEquity is the sole book-running manager. The offering is set to close Feb. 4, 2025, subject to customary conditions, with proceeds primarily allocated to working capital and further clinical development of its lead drug candidate, Buntanetap. To view the full…

TuesdayJan 07, 2025 1:10 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Streamlined Pathway to Advance Buntanetap for AD

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), today announced that the FDA has accepted an updated protocol for the pivotal Phase 3 AD study, which is slated to begin in January 2025. In October 2024, the FDA granted clearance for Annovis to proceed with the pivotal Phase 3 AD studies based on its Phase 2/3 data demonstrating cognitive improvement in early-stage AD patients. The original protocol design proposed two separate trials that are now integrated into a single 6/18-month trial under the…

FridayDec 27, 2024 1:41 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Eyes Opportunities Beyond ‘Year of Significant Progress’

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, was featured in a recent article that discussed the company’s year-end investor webcast, where it provided stakeholders with a comprehensive overview of 2024 milestones and strategic initiatives for 2025. The webcast also highlighted financial developments, including the securing of a $50 million At-The-Market (“ATM”) offering and ongoing strategic efforts to raise additional funds to support clinical trial development and long-term growth. “2024 has been a year of significant progress for Annovis Bio, and we are excited about the opportunities ahead,” Dr. Maria Maccecchini, founder, president…

FridayDec 20, 2024 3:04 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Committed to Ensuring Highest Standards in Continued Buntanetap Trials

Annovis Bio (NYSE: ANVS) is a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases. The company’s lead candidate, buntanetap, is an innovative drug that targets multiple pathways involved in neurodegenerative diseases by inhibiting the production of neurotoxic proteins that lead to the death of neurons, thereby slowing or stopping disease progression. A recent article highlights the company’s successful clinical trials and its receipt of FDA clearance to proceed with a pivotal phase 3 Alzheimer’s disease program for buntanetap, set to begin in early 2025. “Our priority is to bring a safe and effective treatment to patients, and we are…

MondayDec 16, 2024 1:34 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Eyes Clear Path Forward for Buntanetap

Annovis Bio (NYSE: ANVS) is a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, such as Alzheimer’s (“AD”) and Parkinson’s (“PD”). The company concluded the third quarter with the completion of significant milestones and a clear path forward for its lead candidate, buntanetap. “Buntanetap is an innovative drug designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein and TDP43,” reads a recent article. “This multifaceted inhibition improves synaptic transmission and axonal transport, reduces neuroinflammation, and protects nerve cells from dying, positioning buntanetap as a potential breakthrough in treating neurodegenerative diseases.”…

FridayDec 13, 2024 1:00 pm

Annovis Bio Inc. (NYSE: ANVS) Showcases 2024 Achievements and Strategic Vision in Year-End Investor Webcast

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company pioneering transformative therapies for neurodegenerative diseases, recently hosted its Year-End Investor Webcast, providing stakeholders with a comprehensive overview of the company's 2024 milestones and strategic initiatives for 2025. The full webcast is available here: https://youtu.be/NA3kCUZZIpI. During the webcast, Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio, detailed significant progress in the company's pivotal Phase 3 studies for Buntanetap, its lead drug candidate targeting neurodegenerative conditions such as Alzheimer's and Parkinson's diseases. These studies aim to demonstrate both symptomatic relief and disease-modifying effects, aligning with Annovis Bio's mission to address…

ThursdayDec 05, 2024 9:10 am

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO Highlights Innovations in Neurodegenerative Drug Development on Today’s Marketplace

Annovis Bio (NYSE: ANVS), a leader in developing treatments for neurodegenerative diseases, was recently featured on Today’s Marketplace in an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO. Dr. Maccecchini detailed Annovis Bio’s groundbreaking drug development targeting toxic proteins responsible for nerve cell damage in Alzheimer’s and Parkinson’s, as well as the company’s next-phase clinical trials. Emphasizing the broader impact of these diseases on caregivers as well as patients, Dr. Maccecchini shared insights into the meaningful progress Annovis Bio is making. The Today’s Marketplace feature continues to spotlight Annovis Bio’s leadership in addressing critical healthcare challenges, reinforcing its…

TuesdayDec 03, 2024 8:00 am

Annovis Bio Inc. (NYSE: ANVS) to Present Recent Achievements and 2025 Strategic Outlook During Upcoming Live Investor Webcast

The webcast led by Annovis’ Founder, President and CEO, Maria Maccecchini, Ph.D., will take place on Dec. 11, at 4:30 p.m. EST. Dr. Maccecchini will provide a comprehensive view of the company’s recent achievements along with strategic initiatives for 2025, followed by a Q&A session. The company recently received FDA clearance to proceed with a pivotal Phase 3 Alzheimer’s disease program for lead drug candidate buntanetap, set to begin in early 2025. Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), will hold a…

MondayNov 25, 2024 8:25 am

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Schedules Investor Webcast to Share Clinical and Strategic Updates

Annovis Bio (NYSE: ANVS), a clinical-stage company developing therapies for neurodegenerative diseases, will host a live investor webcast on Dec. 11, 2024, at 4:30 PM EST. Led by Founder and CEO Dr. Maria Maccecchini, the event will highlight updates on Phase 3 studies for Parkinson’s and Alzheimer’s diseases, regulatory milestones, financial strategies, and plans for advancing neurodegenerative therapies in 2025. To view the full press release, visit https://ibn.fm/2Ib9D About Annovis Bio Inc. Annovis Bio, headquartered in Malvern, Pennsylvania, is committed to addressing neurodegeneration in diseases such as Alzheimer’s and Parkinson’s. The company is developing innovative therapies that target multiple neurotoxic…

TuesdayNov 19, 2024 2:53 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Paving the Way for NDA Submission

Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on developing transformative therapies for neurodegenerative disorders, including Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), recently achieved a significant milestone in its drug development process. In early October, the company held a meeting with the U.S. Food and Drug Administration (“FDA”), where it received clearance to proceed with pivotal Phase 3 studies for its lead compound, buntanetap. “We are now ready to move into the highly anticipated Phase 3 stage,” Maria Maccecchini, Ph.D., founder, president and CEO of Annovis Bio, was quoted as saying. “Our priority is to bring…

Site Search

Company Search

Tag: Annovis Bio Inc. ANVS